Drugs & Aging

, Volume 21, Issue 11, pp 711–730

The Impact of Fragility Fracture on Health-Related Quality of Life

The Importance of Antifracture Therapy
  • Ted Xenodemetropoulos
  • Shawn Davison
  • George Ioannidis
  • Jonathan D. Adachi
Review Article

Abstract

Both general and specific health status instruments can be utilised in evaluating health-related quality of life (HR-QOL) deficits resulting from osteoporotic fractures. Osteoporotic hip, vertebral and wrist fractures significantly decrease HR-QOL in most HR-QOL domains investigated. The presence of multiple vertebral fractures leads to larger decrements in HR-QOL. More research needs to be completed with these HR-QOL tools to better assess the true burden of osteoporotic fractures, particularly in the case of hip fractures, as the burden is surely being underestimated without recognition of HR-QOL. Only when the burden of fragility fractures is understood, inclusive of HR-QOL, will the value of proven antifracture prevention and treatment therapies be appreciated. Information collected by HR-QOL instruments may provide new insight as to how to improve quality of life for patients with fractures and how to properly allocate healthcare spending.

References

  1. 1.
    National Institutes of Health. Osteoporosis prevention diagnosis and therapy. NIH consensus statement. Natl Instit Health 2000; 17(1): 1–45Google Scholar
  2. 2.
    Lips P. Epidemiology and predictors of fractures associated with osteoporosis. Am J Med 1997; 103(2A): 3S–8SPubMedCrossRefGoogle Scholar
  3. 3.
    Bengner U, Johnell O, Redlund-Johnell I. Increasing incidence of tibia condyle and patella fractures. Acta Orthop Scand 1986; 57(4): 334–6PubMedCrossRefGoogle Scholar
  4. 4.
    Luthje P, Nurmi I, Kataja M, et al. Incidence of pelvic fractures in Finland in 1988. Acta Orthop Scand 1995; 66(3): 245–8PubMedCrossRefGoogle Scholar
  5. 5.
    Rose SH, Melton III LJ, Morrey BF, et al. Epidemiologic features of humeral fractures. Clin Orthop 1982; 168: 24–30PubMedGoogle Scholar
  6. 6.
    Kanis JA, Oden A, Johnell O, et al. The burden of osteoporotic fractures: a method for setting intervention thresholds. Osteoporos Int 2001; 12(5): 417–27PubMedCrossRefGoogle Scholar
  7. 7.
    Nguyen TV, Center JR, Sambrook PN, et al. Risk factors for proximal humerus, forearm, and wrist fractures in elderly men and women: the Dubbo Osteoporosis Epidemiology Study. Am J Epidemiol 2001; 153(6): 587–95PubMedCrossRefGoogle Scholar
  8. 8.
    Melton III LJ, Chrischilles EA, Cooper C, et al. Perspective: how many women have osteoporosis? J Bone Miner Res 1992; 7(9): 1005–10PubMedCrossRefGoogle Scholar
  9. 9.
    Chrischilles EA, Butler CD, Davis CS, et al. A model of lifetime osteoporosis impact. Arch Intern Med 1991; 151(10): 2026–32PubMedCrossRefGoogle Scholar
  10. 10.
    Chrischilles E, Shireman T, Wallace R. Costs and health effects of osteoporotic fractures. Bone 1994; 15(4): 377–86PubMedCrossRefGoogle Scholar
  11. 11.
    Kanis JA, Geusens P, Christiansen C. Guidelines for clinical trials in osteoporosis: a position paper of the European Foundation for Osteoporosis and Bone Disease. Osteoporos Int 1991; 1(3): 182–8PubMedCrossRefGoogle Scholar
  12. 12.
    Reginster JY, Compston JE, Jones EA, et al. Recommendations for the registration of new chemical entities used in the prevention and treatment of osteoporosis. Calcif Tissue Int 1995; 57(4): 247–50PubMedCrossRefGoogle Scholar
  13. 13.
    Silverman SL, Cranney A. Quality of life measurement in osteoporosis. J Rheumatol 1997; 24(6): 1218–21PubMedGoogle Scholar
  14. 14.
    Tosteson AN, Hammond CS. Quality-of-life assessment in osteoporosis: health-status and preference-based measures. Pharmacoeconomics 2002; 20(5): 289–303PubMedCrossRefGoogle Scholar
  15. 15.
    Brown JP, Josse RG. 2002 clinical practice guidelines for the diagnosis and management of osteoporosis in Canada. CMAJ 2002; 167 (10 Suppl.): Sl–34Google Scholar
  16. 16.
    Hallworth RB. Prevention and treatment of postmenopausal osteoporosis. Pharm World Sci 1998; 20(5): 198–205PubMedCrossRefGoogle Scholar
  17. 17.
    Hays RD, Hahn H, Marshall G. Use of the SF-36 and other health-related quality of life measures to assess persons with disabilities. Arch Phys Med Rehabil 2002; 83 (12 Suppl. 2): S4–9PubMedCrossRefGoogle Scholar
  18. 18.
    Cella D, Nowinski CJ. Measuring quality of life in chronic illness: the functional assessment of chronic illness therapy measurement system. Arch Phys Med Rehabil 2002; 83 (12 Suppl. 2): S10–7PubMedCrossRefGoogle Scholar
  19. 19.
    Tulsky DS, Rosenthal M. Measurement of quality of life in rehabilitation medicine: emerging issues. Arch Phys Med Rehabil 2003; 84 (4 Suppl. 2): Sl–2Google Scholar
  20. 20.
    Guyatt GH, Naylor CD, Juniper E, et al. Users’ guides to the medical literature: XII. How to use articles about health-related quality of life. Evidence-Based Medicine Working Group. JAMA 1997; 277(15): 1232–7PubMedCrossRefGoogle Scholar
  21. 21.
    Cook DJ, Guyatt GH, Adachi JD, et al. Development and validation of the mini-osteoporosis quality of life questionnaire (OQLQ) in osteoporotic women with back pain due to vertebral fractures. Osteoporosis Quality of Life Study Group. Osteoporos Int 1999; 10(3): 207–13PubMedCrossRefGoogle Scholar
  22. 22.
    Weinstein MC, Stason WB. Foundations of cost-effectiveness analysis for health and medical practices. N Engl J Med 1977; 296(13): 716–21PubMedCrossRefGoogle Scholar
  23. 23.
    Tosteson AN. Quality of life in the economic evaluation of osteoporosis prevention and treatment. Spine 1997; 22 (24 Suppl.): 58S–62SPubMedCrossRefGoogle Scholar
  24. 24.
    Melton III LJ. Cost-effective treatment strategies for osteoporosis. Osteoporos Int 1999; 9Suppl. 2: S111–6PubMedCrossRefGoogle Scholar
  25. 25.
    Brazier JE, Green C, Kanis JA. A systematic review of health state utility values for osteoporosis-related conditions. Osteoporos Int 2002; 13(10): 768–76PubMedCrossRefGoogle Scholar
  26. 26.
    Ware Jr JE, Sherbourne CD. The MOS 36-item short-form health survey (SF-36): I. Conceptual framework and item selection. Med Care 1992; 30(6): 473–83PubMedCrossRefGoogle Scholar
  27. 27.
    Ware Jr JE, Kosinski M, Gandek B, et al. The factor structure of the SF-36 Health Survey in 10 countries: results from the IQOLA Project. International Quality of Life Assessment. J Clin Epidemiol 1998; 51(11): 1159–65PubMedCrossRefGoogle Scholar
  28. 28.
    Hopman WM, Towheed T, Anastassiades T, et al. Canadian normative data for the SF-36 health survey. Canadian Multi-centre Osteoporosis Study Research Group. CMAJ 2000; 163(3): 265–71PubMedGoogle Scholar
  29. 29.
    Hall SE, Criddle RA, Comito TL, et al. A case-control study of quality of life and functional impairment in women with longstanding vertebral osteoporotic fracture. Osteoporos Int 1999; 9(6): 508–15PubMedCrossRefGoogle Scholar
  30. 30.
    Randell AG, Nguyen TV, Bhalerao N, et al. Deterioration in quality of life following hip fracture: a prospective study. Osteoporos Int 2000; 11(5): 460–6PubMedCrossRefGoogle Scholar
  31. 31.
    Tosteson AN, Gabriel SE, Grove MR, et al. Impact of hip and vertebral fractures on quality-adjusted life years. Osteoporos Int 2001; 12(12): 1042–9PubMedCrossRefGoogle Scholar
  32. 32.
    Lombardi Jr I, Oliveira LM, Monteiro CR, et al. Evaluation of physical capacity and quality of life in osteoporotic women. Osteoporos Int 2004; 15(1): 80–5PubMedCrossRefGoogle Scholar
  33. 33.
    Ethgen O, Tellier V, Sedrine WB, et al. Health-related quality of life and cost of ambulatory care in osteoporosis: how may such outcome measures be valuable information to health decision makers and payers? Bone 2003; 32(6): 718–24PubMedCrossRefGoogle Scholar
  34. 34.
    Horsman J, Furlong W, Feeny D, et al. The Health Utilities Index (HUI®): concepts, measurement properties and applications. Health Qual Life Outcomes 2003; 1(1): 54PubMedCrossRefGoogle Scholar
  35. 35.
    Boyle MH, Furlong W, Feeny D, et al. Reliability of the Health Utilities Index: Mark III used in the 1991 cycle 6 Canadian General Social Survey Health Questionnaire. Qual Life Res 1995; 4(3): 249–57PubMedCrossRefGoogle Scholar
  36. 36.
    Adachi JD, Ioannidis G, Pickard L, et al. The association between osteoporotic fractures and health-related quality of life as measured by the Health Utilities Index in the Canadian Multicentre Osteoporosis Study (CaMos). Osteoporos Int 2003; 14(11): 895–904PubMedCrossRefGoogle Scholar
  37. 37.
    Gabriel SE, Kneeland TS, Melton III LJ, et al. Health-related quality of life in economic evaluations for osteoporosis: whose values should we use? Med Decis Making 1999; 19(2): 141–8PubMedCrossRefGoogle Scholar
  38. 38.
    Tidermark J, Bergstrom G, Svensson O, et al. Responsiveness of the EuroQol (EQ 5-D) and the SF-36 in elderly patients with displaced femoral neck fractures. Qual Life Res 2003; 12(8): 1069–79PubMedCrossRefGoogle Scholar
  39. 39.
    Oleksik A, Lips P, Dawson A, et al. Health-related quality of life in postmenopausal women with low BMD with or without prevalent vertebral fractures. J Bone Miner Res 2000; 15(7): 1384–92PubMedCrossRefGoogle Scholar
  40. 40.
    Cockerill W, Lunt M, Silman AJ, et al. Health-related quality of life and radiographic vertebral fracture. Osteoporos Int 2004; 15(2): 113–9PubMedCrossRefGoogle Scholar
  41. 41.
    Rabin R, de Charro F. EQ-5D: a measure of health status from the EuroQol Group. Ann Med 2001; 33(5): 337–43PubMedCrossRefGoogle Scholar
  42. 42.
    Lydick E, Zimmerman SI, Yawn B, et al. Development and validation of a discriminative quality of life questionnaire for osteoporosis (the OPTQoL). J Bone Miner Res 1997; 12(3): 456–63PubMedCrossRefGoogle Scholar
  43. 43.
    Chandler JM, Martin AR, Girman C, et al. Reliability of an osteoporosis-targeted quality of life survey instrument for use in the community: OPTQoL. Osteoporos Int 1998; 8(2): 127–35PubMedCrossRefGoogle Scholar
  44. 44.
    Martin AR, Sornay-Rendu E, Chandler JM, et al. The impact of osteoporosis on quality-of-life: the OFELY cohort. Bone 2002; 31(1): 32–6PubMedCrossRefGoogle Scholar
  45. 45.
    Lips P, Cooper C, Agnusdei D, et al. Quality of life in patients with vertebral fractures: validation of the Quality of Life Questionnaire of the European Foundation for Osteoporosis (QUALEFFO). Working Party for Quality of Life of the European Foundation for Osteoporosis. Osteoporos Int 1999; 10(2): 150–60PubMedCrossRefGoogle Scholar
  46. 46.
    Falch JA, Bentzen H, Dahl AA. Pain, functional level and emotional problems of women with osteoporosis and vertebral fractures [in Norwegian]. Tidsskr Nor Laegeforen 2004; 123(23): 3355–7Google Scholar
  47. 47.
    Murrell P, Todd CJ, Martin A, et al. Postal administration compared with nurse-supported administration of the QUALEFFO-41 in a population sample: comparison of results and assessment of psychometric properties. Osteoporos Int 2001; 12(8): 672–9PubMedCrossRefGoogle Scholar
  48. 48.
    Kocyigit H, Gulseren S, Erol A, et al. The reliability and validity of the Turkish version of Quality of Life Questionnaire of the European Foundation for Osteoporosis (QUALEFFO). Clin Rheumatol 2003; 22(1): 18–23PubMedCrossRefGoogle Scholar
  49. 49.
    Measuring quality of life in women with osteoporosis. Osteoporosis Quality of Life Study Group. Osteoporos Int 1997; 7(5): 478–87Google Scholar
  50. 50.
    Badia X, Diez-Perez A, Alvarez-Sanz C, et al. Measuring quality of life in women with vertebral fractures due to osteoporosis: a comparison of the OQLQ and QUALEFFO. Qual Life Res 2001; 10(4): 307–17PubMedCrossRefGoogle Scholar
  51. 51.
    Papaioannou A, Adachi JD, Winegard K, et al. Efficacy of home-based exercise for improving quality of life among elderly women with symptomatic osteoporosis-related vertebral fractures. Osteoporos Int 2003; 14(8): 677–82PubMedCrossRefGoogle Scholar
  52. 52.
    Kessenich CR, Guyatt GH, Rosen CJ. Health-related quality of life and participation in osteoporosis clinical trials. Calcif Tissue Int 1998; 62(3): 189–92PubMedCrossRefGoogle Scholar
  53. 53.
    Ioannidis G, Gordon M, Adachi JD. Quality of life in osteoporosis. Nurs Clin North Am 2001; 36(3): 481–9PubMedGoogle Scholar
  54. 54.
    Adachi JD, Ioannidis G, Olszynski, et al. The impact of incident vertebral and non-vertebral fractures on health related quality of life in postmenopausal women. BMC Musculoskelet Disord 2002; 3(1): 11PubMedCrossRefGoogle Scholar
  55. 55.
    Randell AG, Bhalerao N, Nguyen TV, et al. Quality of life in osteoporosis: reliability, consistency, and validity of the Osteoporosis Assessment Questionnaire. J Rheumatol 1998; 25(6): 1171–9PubMedGoogle Scholar
  56. 56.
    Oglesby AK, Minshall ME, Shen W, et al. The impact of incident vertebral and non-vertebral fragility fractures on health-related quality of life in established postmenopausal osteoporosis: results from the teriparatide randomized, placebo-controlled trial in postmenopausal women. J Rheumatol 2003; 30(7): 1579–83PubMedGoogle Scholar
  57. 57.
    Silverman SL, Minshall ME, Shen W, et al. The relationship of health-related quality of life to prevalent and incident vertebral fractures in postmenopausal women with osteoporosis: results from the Multiple Outcomes of Raloxifene Evaluation Study. Arthritis Rheum 2001; 44(11): 2611–9PubMedCrossRefGoogle Scholar
  58. 58.
    Helmes E, Hodsman A, Lazowski D, et al. A questionnaire to evaluate disability in osteoporotic patients with vertebral compression fractures. J Gerontol A Biol Sci Med Sci 1995; 50(2): M91–8PubMedCrossRefGoogle Scholar
  59. 59.
    Marquis P, Cialdella P, De la LC. Development and validation of a specific quality of life module in post-menopausal women with osteoporosis: the QUALIOST. Qual Life Res 2001; 10(6): 555–66PubMedCrossRefGoogle Scholar
  60. 60.
    Greendale GA, Barrett-Connor E, Ingles S, et al. Late physical and functional effects of osteoporotic fracture in women: the Rancho Bernardo Study. J Am Geriatr Soc 1995; 43(9): 955–61PubMedGoogle Scholar
  61. 61.
    Adachi JD, Ioannidis G, Berger C, et al. The influence of osteoporotic fractures on health-related quality of life in community-dwelling men and women across Canada. Osteoporos Int 2001; 12(11): 903–8PubMedCrossRefGoogle Scholar
  62. 62.
    Salkeld G, Cameron ID, Cumming RG, et al. Quality of life related to fear of falling and hip fracture in older women: a time trade off study. BMJ 2000; 320(7231): 341–6PubMedCrossRefGoogle Scholar
  63. 63.
    Cummings SR, Phillips SL, Wheat ME, et al. Recovery of function after hip fracture: the role of social supports. J Am Geriatr Soc 1988; 36(9): 801–6PubMedGoogle Scholar
  64. 64.
    Magaziner J, Simonsick EM, Kashner TM, et al. Predictors of functional recovery one year following hospital discharge for hip fracture: a prospective study. J Gerontol 1990; 45(3): M101–7PubMedCrossRefGoogle Scholar
  65. 65.
    Marottoli RA, Berkman LF, Cooney Jr LM. Decline in physical function following hip fracture. J Am Geriatr Soc 1992; 40(9): 861–6PubMedGoogle Scholar
  66. 66.
    Koot VC, Peeters PH, de Jong JR, et al. Functional results after treatment of hip fracture: a multicentre, prospective study in 215 patients. Eur J Surg 2000; 166(6): 480–5PubMedCrossRefGoogle Scholar
  67. 67.
    Papaioannou A, Watts NB, Kendler DL, et al. Diagnosis and management of vertebral fractures in elderly adults. Am J Med 2002; 113(3): 220–8PubMedCrossRefGoogle Scholar
  68. 68.
    Cook DJ, Guyatt GH, Adachi JD, et al. Quality of life issues in women with vertebral fractures due to osteoporosis. Arthritis Rheum 1993; 36(6): 750–6PubMedCrossRefGoogle Scholar
  69. 69.
    Huang C, Ross PD, Wasnich RD. Vertebral fracture and other predictors of physical impairment and health care utilization. Arch Intern Med 1996; 156(21): 2469–75PubMedCrossRefGoogle Scholar
  70. 70.
    Burger H, Van Daele PL, Grashuis K, et al. Vertebral deformities and functional impairment in men and women. J Bone Miner Res 1997; 12(1): 152–7PubMedCrossRefGoogle Scholar
  71. 71.
    Rapado A. General management of vertebral fractures. Bone 1996; 18 (3 Suppl.): 191S–6SPubMedCrossRefGoogle Scholar
  72. 72.
    Gold DT. The clinical impact of vertebral fractures: quality of life in women with osteoporosis. Bone 1996; 18 (3 Suppl.): 185S–9SPubMedCrossRefGoogle Scholar
  73. 73.
    Nevitt MC, Ettinger B, Black DM, et al. The association of radiographically detected vertebral fractures with back pain and function: a prospective study. Ann Intern Med 1998; 128(10): 793–800PubMedGoogle Scholar
  74. 74.
    Begerow B, Pfeifer M, Pospeschill M, et al. Time since vertebral fracture: an important variable concerning quality of life in patients with postmenopausal osteoporosis. Osteoporos Int 1999; 10(1): 26–33PubMedCrossRefGoogle Scholar
  75. 75.
    Black DM, Cummings SR, Karpf DB, et al. Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group. Lancet 1996; 348(9041): 1535–41PubMedCrossRefGoogle Scholar
  76. 76.
    Cooper C, Atkinson EJ, O’Fallon WM, et al. Incidence of clinically diagnosed vertebral fractures: a population-based study in Rochester, Minnesota, 1985–1989. J Bone Miner Res 1992; 7(2): 221–7PubMedCrossRefGoogle Scholar
  77. 77.
    Nevitt MC, Thompson DE, Black DM, et al. Effect of alendronate on limited-activity days and bed-disability days caused by back pain in postmenopausal women with existing vertebral fractures. Fracture Intervention Trial Research Group. Arch Intern Med 2000; 160(1): 77–85PubMedCrossRefGoogle Scholar
  78. 78.
    Altissimi M, Antenucci R, Fiacca C, et al. Long-term results of conservative treatment of fractures of the distal radius. Clin Orthop 1986; 206: 202–10PubMedGoogle Scholar
  79. 79.
    Field J, Warwick D, Bannister GC, et al. Long-term prognosis of displaced Colles’ fracture: a 10-year prospective review. Injury 1992; 23(8): 529–32PubMedCrossRefGoogle Scholar
  80. 80.
    Warwick D, Field J, Prothero D, et al. Function ten years after Colles’ fracture. Clin Orthop 1993; 295: 270–4PubMedGoogle Scholar
  81. 81.
    de Bruijn HP. Functional treatment of Colles fracture. Acta Orthop Scand Suppl 1987; 223: 1–95PubMedGoogle Scholar
  82. 82.
    Kaukonen JP, Karaharju EO, Porras M, et al. Functional recovery after fractures of the distal forearm: analysis of radiographic and other factors affecting the outcome. Ann Chir Gynaecol 1988; 77(1): 27–31PubMedGoogle Scholar
  83. 83.
    Dolan P, Torgerson D, Kakarlapudi TK. Health-related quality of life of Colles’ fracture patients. Osteoporos Int 1999; 9(3): 196–9PubMedCrossRefGoogle Scholar
  84. 84.
    Lindsay R, Silverman SL, Cooper C, et al. Risk of new vertebral fracture in the year following a fracture. JAMA 2001; 285(3): 320–3PubMedCrossRefGoogle Scholar
  85. 85.
    Russell RG, Rogers MJ. Bisphosphonates: from the laboratory to the clinic and back again. Bone 1999; 25(1): 97–106PubMedCrossRefGoogle Scholar
  86. 86.
    Harris ST, Watts NB, Jackson RD, et al. Four-year study of intermittent cyclic etidronate treatment of postmenopausal osteoporosis: three years of blinded therapy followed by one year of open therapy. Am J Med 1993; 95(6): 557–67PubMedCrossRefGoogle Scholar
  87. 87.
    Storm T, Thamsborg G, Steiniche T, et al. Effect of intermittent cyclical etidronate therapy on bone mass and fracture rate in women with postmenopausal osteoporosis. N Engl J Med 1990; 322(18): 1265–71PubMedCrossRefGoogle Scholar
  88. 88.
    Watts NB, Harris ST, Genant HK, et al. Intermittent cyclical etidronate treatment of postmenopausal osteoporosis. N Engl J Med 1990; 323(2): 73–9PubMedCrossRefGoogle Scholar
  89. 89.
    van Staa TP, Abenhaim L, Cooper C. Use of cyclical etidronate and prevention of non-vertebral fractures. Br J Rheumatol 1998; 37(1): 87–94PubMedCrossRefGoogle Scholar
  90. 90.
    Miller PD, Watts NB, Licata AA, et al. Cyclical etidronate in the treatment of postmenopausal osteoporosis: efficacy and safety after seven years of treatment. Am J Med 1997; 103(6): 468–76PubMedCrossRefGoogle Scholar
  91. 91.
    Burger H, Herings RM, Egberts AC, et al. Cyclical etidronate use is not associated with symptoms of peptic ulcer disease. Eur J Clin Pharmacol 2000; 56(4): 319–22PubMedCrossRefGoogle Scholar
  92. 92.
    van Staa TP, Leufkens H, Abenhaim L, et al. Postmarketing surveillance of the safety of cyclic etidronate. Pharmacotherapy 1998; 18(5): 1121–8PubMedGoogle Scholar
  93. 93.
    Kherani RB, Papaioannou A, Adachi JD. Long-term tolerability of the bisphosphonates in postmenopausal osteoporosis: a comparative review. Drug Saf 2002; 25(11): 781–90PubMedCrossRefGoogle Scholar
  94. 94.
    Chesnut III CH, McClung MR, Ensrud KE, et al. Alendronate treatment of the postmenopausal osteoporotic woman: effect of multiple dosages on bone mass and bone remodeling. Am J Med 1995; 99(2): 144–52PubMedCrossRefGoogle Scholar
  95. 95.
    Devogelaer JP, Broil H, Correa-Rotter R, et al. Oral alendronate induces progressive increases in bone mass of the spine, hip, and total body over 3 years in postmenopausal women with osteoporosis. Bone 1996; 18(2): 141–50PubMedCrossRefGoogle Scholar
  96. 96.
    Liberman UA, Weiss SR, Broil J, et al. Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. The Alendronate Phase III Osteoporosis Treatment Study Group. N Engl J Med 1995; 333(22): 1437–43PubMedCrossRefGoogle Scholar
  97. 97.
    Cummings SR, Black DM, Thompson DE, et al. Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial. JAMA 1998; 280(24): 2077–82PubMedCrossRefGoogle Scholar
  98. 98.
    Black DM, Thompson DE, Bauer DC, et al. Fracture risk reduction with alendronate in women with osteoporosis: the Fracture Intervention Trial. FIT Research Group. J Clin Endocrinol Metab 2000; 85(11): 4118–24PubMedCrossRefGoogle Scholar
  99. 99.
    Pols HA, Felsenberg D, Hanley DA, et al. Multinational, placebo-controlled, randomized trial of the effects of alendronate on bone density and fracture risk in postmenopausal women with low bone mass: results of the FOSIT study. Foxamax International Trial Study Group. Osteoporos Int 1999; 9(5): 461–8PubMedCrossRefGoogle Scholar
  100. 100.
    McClung M, Clemmesen B, Daifotis A, et al. Alendronate prevents postmenopausal bone loss in women without osteoporosis: a double-blind, randomized, controlled trial. Alendronate Osteoporosis Prevention Study Group. Ann Intern Med 1998; 128(4): 253–61PubMedGoogle Scholar
  101. 101.
    Levis S, Quandt SA, Thompson D, et al. Alendronate reduces the risk of multiple symptomatic fractures: results from the fracture intervention trial. J Am Geriatr Soc 2002; 50(3): 409–15PubMedCrossRefGoogle Scholar
  102. 102.
    Chrischilles EA, Dasbach EJ, Rubenstein LM, et al. The effect of alendronate on fracture-related healthcare utilization and costs: the fracture intervention trial. Osteoporos Int 2001; 12(8): 654–60PubMedCrossRefGoogle Scholar
  103. 103.
    Liberman UI, Hirsch LJ. Esophagitis and alendronate. N Engl J Med 1996; 335(14): 1069–70PubMedCrossRefGoogle Scholar
  104. 104.
    Bauer DC, Black D, Ensrud K, et al. Upper gastrointestinal tract safety profile of alendronate: the fracture intervention trial. Arch Intern Med 2000; 160(4): 517–25PubMedCrossRefGoogle Scholar
  105. 105.
    Schnitzer T, Bone HG, Crepaldi G, et al. Therapeutic equivalence of alendronate 70mg once-weekly and alendronate 10mg daily in the treatment of osteoporosis. Alendronate Once-Weekly Study Group. Aging (Milano) 2000; 12(1): 1–12Google Scholar
  106. 106.
    Greenspan S, Field-Munves E, Tonino R, et al. Tolerability of once-weekly alendronate in patients with osteoporosis: a randomized, double-blind, placebo-controlled study. Mayo Clin Proc 2002; 77(10): 1044–52PubMedCrossRefGoogle Scholar
  107. 107.
    Lanza F, Sahba B, Schwartz H, et al. The upper GI safety and tolerability of oral alendronate at a dose of 70 milligrams once weekly: a placebo-controlled endoscopy study. Am J Gastroenterol 2002; 97(1): 58–64PubMedCrossRefGoogle Scholar
  108. 108.
    Ettinger B, Pressman A, Schein J. Clinic visits and hospital admissions for care of acid-related upper gastrointestinal disorders in women using alendronate for osteoporosis. Am J Manag Care 1998; 4(10): 1377–82PubMedGoogle Scholar
  109. 109.
    Donahue JG, Chan KA, Andrade SE, et al. Gastric and duodenal safety of daily alendronate. Arch Intern Med 2002; 162(8): 936–42PubMedCrossRefGoogle Scholar
  110. 110.
    McClung MR, Geusens P, Miller PD, et al. Effect of risedronate on the risk of hip fracture in elderly women. Hip Intervention Program Study Group. N Engl J Med 2001; 344(5): 333–40PubMedCrossRefGoogle Scholar
  111. 111.
    Harris ST, Watts NB, Genant HK, et al. Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. Vertebral Efficacy With Risedronate Therapy (VERT) Study Group. JAMA 1999; 282(14): 1344–52PubMedCrossRefGoogle Scholar
  112. 112.
    Reginster J, Minne HW, Sorensen OH, et al. Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Vertebral Efficacy with Risedronate Therapy (VERT) Study Group. Osteoporos Int 2000; 11(1): 83–91PubMedCrossRefGoogle Scholar
  113. 113.
    Sorensen OH, Crawford GM, Mulder H, et al. Long-term efficacy of risedronate: a 5-year placebo-controlled clinical experience. Bone 2003; 32(2): 120–6PubMedCrossRefGoogle Scholar
  114. 114.
    Peters ML, Leonard M, Licata AA. Role of alendronate and risedronate in preventing and treating osteoporosis. Cleve Clin J Med 2001; 68(11): 945–51PubMedCrossRefGoogle Scholar
  115. 115.
    Lanza FL, Hunt RH, Thomson AB, et al. Endoscopic comparison of esophageal and gastroduodenal effects of risedronate and alendronate in postmenopausal women. Gastroenterology 2000; 119(3): 631–8PubMedCrossRefGoogle Scholar
  116. 116.
    Thomson AB, Marshall JK, Hunt RH, et al. 14 day endoscopy study comparing risedronate and alendronate in postmenopausal women stratified by Helicobacter pylori status. J Rheumatol 2002; 29(9): 1965–74PubMedGoogle Scholar
  117. 117.
    Lanza F, Schwartz H, Sahba B, et al. An endoscopic comparison of the effects of alendronate and risedronate on upper gastrointestinal mucosae. Am J Gastroenterol 2000; 95(11): 3112–7PubMedCrossRefGoogle Scholar
  118. 118.
    Taggart H, Bolognese MA, Lindsay R, et al. Upper gastrointestinal tract safety of risedronate: a pooled analysis of 9 clinical trials. Mayo Clin Proc 2002; 77(3): 262–70PubMedCrossRefGoogle Scholar
  119. 119.
    Adachi JD, Adami S, Miller PD, et al. Tolerability of risedronate in postmenopausal women intolerant of alendronate. Aging (Milano) 2001; 13(5): 347–54Google Scholar
  120. 120.
    Chesnut III CH, Silverman S, Andriano K, et al. A randomized trial of nasal spray salmon calcitonin in postmenopausal women with established osteoporosis: the prevent recurrence of osteoporotic fractures study. PROOF Study Group. Am J Med 2000; 109(4): 267–76PubMedCrossRefGoogle Scholar
  121. 121.
    Reginster JY, Deroisy R, Lecart MP, et al. A double-blind, placebo-controlled, dose-finding trial of intermittent nasal salmon calcitonin for prevention of postmenopausal lumbar spine bone loss. Am J Med 1995; 98(5): 452–8PubMedCrossRefGoogle Scholar
  122. 122.
    Reginster JY, Meurmans L, Deroisy R, et al. A 5-year controlled randomized study of prevention of postmenopausal trabecular bone loss with nasal salmon calcitonin and calcium. Eur J Clin Invest 1994; 24(8): 565–9PubMedCrossRefGoogle Scholar
  123. 123.
    Ellerington MC, Hillard TC, Whitcroft SI, et al. Intranasal salmon calcitonin for the prevention and treatment of postmenopausal osteoporosis. Calcif Tissue Int 1996; 59(1): 6–11PubMedCrossRefGoogle Scholar
  124. 124.
    Overgaard K, Hansen MA, Jensen SB, et al. Effect of salcatonin given intranasally on bone mass and fracture rates in established osteoporosis: a dose-response study. BMJ 1992; 305(6853): 556–61PubMedCrossRefGoogle Scholar
  125. 125.
    Lyritis GP, Ioannidis GV, Karachalios T, et al. Analgesic effect of salmon calcitonin suppositories in patients with acute pain due to recent osteoporotic vertebral crush fractures: a prospective double-blind, randomized, placebo-controlled clinical study. Clin J Pain 1999; 15(4): 284–9PubMedCrossRefGoogle Scholar
  126. 126.
    Lyritis GP, Paspati I, Karachalios T, et al. Pain relief from nasal salmon calcitonin in osteoporotic vertebral crush fractures: a double blind, placebo-controlled clinical study. Acta Orthop Scand Suppl 1997; 275: 112–4PubMedGoogle Scholar
  127. 127.
    Pun KK, Chan LW. Analgesic effect of intranasal salmon calcitonin in the treatment of osteoporotic vertebral fractures. Clin Ther 1989; 11(2): 205–9PubMedGoogle Scholar
  128. 128.
    Balasch J. Sex steroids and bone: current perspectives. Hum Reprod Update 2003; 9(3): 207–22PubMedCrossRefGoogle Scholar
  129. 129.
    Ettinger B, Pressman A, Sklarin P, et al. Associations between low levels of serum estradiol, bone density, and fractures among elderly women: the study of osteoporotic fractures. J Clin Endocrinol Metab 1998; 83(7): 2239–43PubMedCrossRefGoogle Scholar
  130. 130.
    Cummings SR, Browner WS, Bauer D, et al. Endogenous hormones and the risk of hip and vertebral fractures among older women. Study of Osteoporotic Fractures Research Group. N Engl J Med 1998; 339(11): 733–8PubMedCrossRefGoogle Scholar
  131. 131.
    Wells G, Tugwell P, Shea B, et al. Meta-analyses of therapies for postmenopausal osteoporosis: V. meta-analysis of the efficacy of hormone replacement therapy in treating and preventing osteoporosis in postmenopausal women. Endocr Rev 2002; 23(4): 529–39PubMedCrossRefGoogle Scholar
  132. 132.
    Torgerson DJ, Bell-Syer SE. Hormone replacement therapy and prevention of vertebral fractures: a meta-analysis of randomised trials. BMC Musculoskelet Disord 2001; 2(1): 7PubMedCrossRefGoogle Scholar
  133. 133.
    Torgerson DJ, Bell-Syer SE. Hormone replacement therapy and prevention of nonvertebral fractures: a meta-analysis of randomized trials. JAMA 2001; 285(22): 2891–7PubMedCrossRefGoogle Scholar
  134. 134.
    Rossouw JE, Anderson GL, Prentice RL, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women’s Health Initiative randomized controlled trial. JAMA 2002; 288(3): 321–33PubMedCrossRefGoogle Scholar
  135. 135.
    Torgerson DJ, Bell-Syer SE. Hormone replacement therapy and prevention of nonvertebral fractures: a meta-analysis of randomized trials. JAMA 2001; 285(22): 2891–7PubMedCrossRefGoogle Scholar
  136. 136.
    Wiklund I, Karlberg J, Mattsson LA. Quality of life of postmenopausal women on a regimen of transdermal estradiol therapy: a double-blind placebo-controlled study. Am J Obstet Gynecol 1993; 168 (3 Pt 1): 824–30PubMedGoogle Scholar
  137. 137.
    Gambacciani M, Ciaponi M, Cappagli B, et al. Effects of low-dose, continuous combined estradiol and noretisterone acetate on menopausal quality of life in early postmenopausal women. Maturitas 2003; 44(2): 157–63PubMedCrossRefGoogle Scholar
  138. 138.
    Tosteson AN, Gabriel SE, Kneeland TS, et al. Has the impact of hormone replacement therapy on health-related quality of life been undervalued? J Womens Health Gend Based Med 2000; 9(2): 119–30PubMedCrossRefGoogle Scholar
  139. 139.
    Hays J, Ockene JK, Brunner RL, et al. Effects of estrogen plus progestin on health-related quality of life. N Engl J Med 2003; 348(19): 1839–54PubMedCrossRefGoogle Scholar
  140. 140.
    Grese TA, Sluka JP, Bryant HU, et al. Molecular determinants of tissue selectivity in estrogen receptor modulators. Proc Natl Acad Sci U S A 1997; 94(25): 14105–10PubMedCrossRefGoogle Scholar
  141. 141.
    Jolly EE, Bjarnason NH, Neven P, et al. Prevention of osteoporosis and uterine effects in postmenopausal women taking raloxifene for 5 years. Menopause 2003; 10(4): 337–44PubMedCrossRefGoogle Scholar
  142. 142.
    Ettinger B, Black DM, Mitlak BH, et al. Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators. JAMA 1999; 282(7): 637–45PubMedCrossRefGoogle Scholar
  143. 143.
    Delmas PD, Bjarnason NH, Mitlak BH, et al. Effects of raloxifene on bone mineral density, serum cholesterol concentrations, and uterine endometrium in postmenopausal women. N Engl J Med 1997; 337(23): 1641–7PubMedCrossRefGoogle Scholar
  144. 144.
    Maricic M, Adachi JD, Sarkar S, et al. Early effects of raloxifene on clinical vertebral fractures at 12 months in postmenopausal women with osteoporosis. Arch Intern Med 2002; 162(10): 1140–3PubMedCrossRefGoogle Scholar
  145. 145.
    Delmas PD, Ensrud KE, Adachi JD, et al. Efficacy of raloxifene on vertebral fracture risk reduction in postmenopausal women with osteoporosis: four-year results from a randomized clinical trial. J Clin Endocrinol Metab 2002; 87(8): 3609–17PubMedCrossRefGoogle Scholar
  146. 146.
    Siris E, Adachi JD, Lu Y, et al. Effects of raloxifene on fracture severity in postmenopausal women with osteoporosis: results from the MORE study. Multiple Outcomes of Raloxifene Evaluation. Osteoporos Int 2002; 13(11): 907–13PubMedCrossRefGoogle Scholar
  147. 147.
    Cauley JA, Norton L, Lippman ME, et al. Continued breast cancer risk reduction in postmenopausal women treated with raloxifene: 4-year results from the MORE trial. Multiple outcomes of raloxifene evaluation. Breast Cancer Res Treat 2001; 65(2): 125–34PubMedCrossRefGoogle Scholar
  148. 148.
    Barrett-Connor E, Grady D, Sashegyi A, et al. Raloxifene and cardiovascular events in osteoporotic postmenopausal women: four-year results from the MORE (Multiple Outcomes of Raloxifene Evaluation) randomized trial. JAMA 2002; 287(7): 847–57PubMedCrossRefGoogle Scholar
  149. 149.
    Barrett-Connor E, Ensrud KE, et al. Post hoc analysis of data from the Multiple Outcomes of Raloxifene Evaluation (MORE) trial on the effects of three years of raloxifene treatment on glycemic control and cardiovascular disease risk factors in women with and without type 2 diabetes. Clin Ther 2003; 25(3): 919–30PubMedCrossRefGoogle Scholar
  150. 150.
    Davies GC, Huster WJ, Lu Y, et al. Adverse events reported by postmenopausal women in controlled trials with raloxifene. Obstet Gynecol 1999; 93(4): 558–65PubMedCrossRefGoogle Scholar

Copyright information

© Adis Data Information BV 2004

Authors and Affiliations

  • Ted Xenodemetropoulos
    • 1
  • Shawn Davison
    • 1
  • George Ioannidis
    • 1
  • Jonathan D. Adachi
    • 1
  1. 1.St Joseph’s HealthcareMcMaster UniversityHamiltonCanada
  2. 2.St Josephs HospitalMc-Master UniversityHamiltonCanada

Personalised recommendations